New cancer drug targets notorious KRAS mutation in first human tests

NCT ID NCT06227377

Summary

This is the first human study of an experimental drug called QTX3034 for people with advanced solid tumors that have a specific genetic change called KRASG12D. The trial aims to find the safest dose and see how well the drug works, either alone or combined with an existing cancer drug called cetuximab. It will enroll about 250 adults whose cancer has progressed despite prior treatments.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SOLID TUMORS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Duke University

    RECRUITING

    Durham, North Carolina, 27710, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Florida Cancer Specialists

    RECRUITING

    Sarasota, Florida, 34232, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • MD Anderson

    RECRUITING

    Houston, Texas, 77030, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Moffitt Cancer Center

    RECRUITING

    Tampa, Florida, 33612, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Montefiore Medical Center

    RECRUITING

    The Bronx, New York, 10461, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • NEXT Oncology Virginia

    RECRUITING

    Fairfax, Virginia, 22031, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • NYU Langone Health

    RECRUITING

    New York, New York, 10016, United States

    Contact Email: •••••@•••••

  • SCRI- Nashville

    RECRUITING

    Nashville, Tennessee, 37203, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • START San Antonio, LLC

    RECRUITING

    San Antonio, Texas, 78229, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Sarah Cannon Research Institute (SCRI)

    RECRUITING

    Denver, Colorado, 80218, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Stephenson Cancer Center

    RECRUITING

    Oklahoma City, Oklahoma, 73104, United States

    Contact Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • UCLA Hematology/Oncology

    RECRUITING

    Los Angeles, California, 90095, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • University of Utah, Huntsman Cancer Center

    RECRUITING

    Salt Lake City, Utah, 84112, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Yale Cancer Center

    RECRUITING

    New Haven, Connecticut, 06511, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.